Skip to content
10-Q

Quarterly Report

Silo Pharma, Inc. SILO

0001213900-26-056079

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 16.27M sh
Shares Diluted Q1 2026 · Mar 31, 2026 13.71M sh
Shares Diluted Q1 2026 · Mar 31, 2025 4.48M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$822.62K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.64M
Short Term Investments Q1 2026 · Mar 31, 2026 $2.13M
Short Term Investments Q1 2026 · Dec 31, 2025 $2.11M
Short Term Investments Q1 2026 · Mar 31, 2025 $2.31M
Short Term Investments Q1 2026 · Dec 31, 2024 $3.17M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $3.9M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.75M
Stockholders Equity Q1 2026 · Mar 31, 2026 $5.68M
Stockholders Equity Q1 2026 · Dec 31, 2025 $6.31M
Stockholders Equity Q1 2026 · Mar 31, 2025 $4.01M
Stockholders Equity Q1 2026 · Dec 31, 2024 $5.03M
Current Liabilities Q1 2026 · Mar 31, 2026 $704.85K
Current Liabilities Q1 2026 · Dec 31, 2025 $650.18K
Total Liabilities Q1 2026 · Mar 31, 2026 $1.34M
Total Liabilities Q1 2026 · Dec 31, 2025 $1.3M
Current Assets Q1 2026 · Mar 31, 2026 $6.8M
Current Assets Q1 2026 · Dec 31, 2025 $7.39M
Total Assets Q1 2026 · Mar 31, 2026 $7.02M
Total Assets Q1 2026 · Dec 31, 2025 $7.61M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.12
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.23
Eps Basic Q1 2026 · Mar 31, 2026 −$0.12
Eps Basic Q1 2026 · Mar 31, 2025 −$0.23
Rd Expense Q1 2026 · Mar 31, 2026 $1.01M
Rd Expense Q1 2026 · Mar 31, 2025 $593.96K
Net Income Q1 2026 · Mar 31, 2026 −$1.65M
Net Income Q1 2026 · Mar 31, 2025 −$1.03M
Operating Income Q1 2026 · Mar 31, 2026 −$1.59M
Operating Income Q1 2026 · Mar 31, 2025 −$1.09M
Gross Profit Q1 2026 · Mar 31, 2026 −$2.66K
Gross Profit Q1 2026 · Mar 31, 2025 $16.57K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $20.69K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $1.46K
Revenue Q1 2026 · Mar 31, 2026 $18.03K
Revenue Q1 2026 · Mar 31, 2025 $18.03K